# Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study

> **NCT05653193** · PHASE2 · RECRUITING · sponsor: **Manchester University NHS Foundation Trust** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Pulmonary Aspergillosis
- Aspergillosis

## Interventions

- **DRUG:** Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care
- **DRUG:** Antifungals as standard of care

## Key facts

- **NCT ID:** NCT05653193
- **Lead sponsor:** Manchester University NHS Foundation Trust
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-17
- **Primary completion:** 2026-11
- **Final completion:** 2026-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653193, "Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05653193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*